Form 4: BioMarin Pharmaceutical Inc. Director Acquires Shares Through Restricted Stock Units

Director Robert J. Hombach acquired 6,650 shares of BioMarin Pharmaceutical Inc. through restricted stock units on May 20, 2025.

Summary

• Robert J. Hombach, a director of BioMarin Pharmaceutical Inc., reported a transaction involving the acquisition of company stock.
• On May 20, 2025, Hombach acquired 6,650 shares of common stock through the grant of restricted stock units.
• The price per share for the restricted stock units was $0.
• Following the transaction, Hombach's total beneficial ownership of BioMarin common stock is 41,870 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock acquisition by a director, which is neither overwhelmingly positive nor negative.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

This type of transaction is common for directors and executives in publicly traded companies, often as part of their compensation packages to align their interests with those of shareholders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a company director.

Key Dates

Keywords

BioMarin Pharmaceutical, Director, Stock Acquisition, Restricted Stock Units, BMRN, Beneficial Ownership, Form 4